<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_1905-7415.1002.478_s_001_w2aab3b7b8b1b6b1aab1c16b1Aa"><h3>Background</h3><p>MicroRNA-34a (miR-34a) contributes to liver injury through an apoptosis pathway.</p></sec><sec id="j_1905-7415.1002.478_s_002_w2aab3b7b8b1b6b1aab1c16b2Aa"><h3>Objective</h3><p>To determine the correlation between serum miR-34a and liver inflammation as assessed by nonalcoholic fatty liver disease (NAFLD) activity score (NAS).</p></sec><sec id="j_1905-7415.1002.478_s_003_w2aab3b7b8b1b6b1aab1c16b3Aa"><h3>Method</h3><p>We included a cross-selectional study of 50 patients with NAFLD in this observational study and confirmed diagnosis by liver biopsy, with NAS grading. A control group comprised 23 healthy individuals without chronic liver disease. Serum miR-34a was assayed using a real-time quantitative PCR (Applied Biosystems).</p></sec><sec id="j_1905-7415.1002.478_s_004_w2aab3b7b8b1b6b1aab1c16b4Aa"><h3>Result</h3><p>The mean age of NAFLD patients was 46.0 ± 13.7 years, and 52% were female. Metabolic syndrome was found in 76%. Liver histopathology showed that 54% of patients had NAS ≥4 and significant fibrosis (≥2) was found in 22%. Serum levels of miR-34a were significantly correlated with NAS (r = 0.39, P = 0.005), and the degree of steatosis (r = 0.28, P = 0.049), ballooning (r = 0.30, P = 0.034), and fibrosis (r = 0.39, P = 0.005). Serum miR-34a in patients with NAS ≥4 was significantly higher than in those with NAS &lt;4 (P = 0.011) and controls (P &lt; 0.001). There was no significant correlation between serum miR-34a and other variables. The area under receiver operating characteristic curve for serum miR-34a comparing patients with NAS ≥4 and with NAS &lt;4 was 0.67 (95% CI 0.52, 0.82).</p></sec><sec id="j_1905-7415.1002.478_s_005_w2aab3b7b8b1b6b1aab1c16b5Aa"><h3>Conclusion</h3><p>Serum level of miR-34a has a significant fair to good correlation with NAS and may serve as a biomarker of liver inflammation and fibrosis in patients with NAFLD.</p></sec></abstract>

BackgroundMicroRNA-34a (miR-34a) contributes to liver injury through an apoptosis pathway.ObjectiveTo determine the correlation between serum miR-34a and liver inflammation as assessed by nonalcoholic fatty liver disease (NAFLD) activity score (NAS).MethodWe included a cross-selectional study of 50 patients with NAFLD in this observational study and confirmed diagnosis by liver biopsy, with NAS grading. A control group comprised 23 healthy individuals without chronic liver disease. Serum miR-34a was assayed using a real-time quantitative PCR (Applied Biosystems).ResultThe mean age of NAFLD patients was 46.0 ± 13.7 years, and 52% were female. Metabolic syndrome was found in 76%. Liver histopathology showed that 54% of patients had NAS ≥4 and significant fibrosis (≥2) was found in 22%. Serum levels of miR-34a were significantly correlated with NAS (r = 0.39, P = 0.005), and the degree of steatosis (r = 0.28, P = 0.049), ballooning (r = 0.30, P = 0.034), and fibrosis (r = 0.39, P = 0.005). Serum miR-34a in patients with NAS ≥4 was significantly higher than in those with NAS <4 (P = 0.011) and controls (P < 0.001). There was no significant correlation between serum miR-34a and other variables. The area under receiver operating characteristic curve for serum miR-34a comparing patients with NAS ≥4 and with NAS <4 was 0.67 (95% CI 0.52, 0.82).ConclusionSerum level of miR-34a has a significant fair to good correlation with NAS and may serve as a biomarker of liver inflammation and fibrosis in patients with NAFLD.

Serum microRNA-34a is potential biomarker for inflammation in nonalcoholic fatty liver disease

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

BackgroundMicroRNA-34a (miR-34a) contributes to liver injury through an apoptosis pathway.ObjectiveTo determine the correlation between serum miR-34a and liver...

Serum microRNA-34a is potential biomarker for inflammation in nonalcoholic fatty liver disease

Article Category: Brief communication (Original)

Published Online: Jan 31, 2017

Page range: 163 - 171

DOI: https://doi.org/10.5372/1905-7415.1002.478

Keywords
Biomarker, microRNA-34a, non-alcoholic fatty liver disease

© 2016 Puth Muangpaisarn, Kanisa Jampoka, Sunchai Payungporn, Naruemon Wisedopas, Chalermrat Bunchorntavakul, Pisit Tangkijvanich, Sombat Treeprasertsuk

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Serum microRNA-34a is potential biomarker for inflammation in nonalcoholic fatty liver disease

Article Category: Brief communication (Original)

Published Online: Jan 31, 2017

Page range: 163 - 171

DOI: https://doi.org/10.5372/1905-7415.1002.478

KeywordsBiomarker, microRNA-34a, non-alcoholic fatty liver disease

© 2016 Puth Muangpaisarn, Kanisa Jampoka, Sunchai Payungporn, Naruemon Wisedopas, Chalermrat Bunchorntavakul, Pisit Tangkijvanich, Sombat Treeprasertsuk

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Keywords
Biomarker, microRNA-34a, non-alcoholic fatty liver disease